glp-1 receptor agonists should be avoided in patients with Impact of GLP- 1 Agonist Therapy High Risk for Sarcopenia | Current Nutrition Reports GLP-1 receptor agonists and next-generation

Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, et al

Common Research Design Considerations Investigators working with copper-binding tripeptides such as AHK-Cu frequently structure studies around in vitro fibroblast or keratinocyte culture models to assess proliferative and gene expression responses, alongside biochemical assays evaluating antioxidant enzyme activity

Risk is elevated in patients with a history of abdominal surgery, chronic acid-suppressing medication use, hypothyroidism, diabetes, immune deficiency, or connective tissue disorders

Full-spectrum CBD is likely to cause reactions here

Ethics approval and consent to participate This work was conducted in accordance with the ethical principles of the Declaration of Helsinki and the Institutional Review Board at the University of California, Los Angeles approved all study procedures (#24-000917)